201 related articles for article (PubMed ID: 22755439)
21. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.
Cooper JE; Gralla J; Chan L; Wiseman AC
Clin Transpl; 2011; ():359-64. PubMed ID: 22755431
[TBL] [Abstract][Full Text] [Related]
22. Understanding the significance of low-level preformed donor-specific anti-HLA antibodies in renal transplant patients.
Wu P; Everly MJ; Jin J; Mao Y; Chen J
Clin Transpl; 2011; ():365-8. PubMed ID: 22755432
[TBL] [Abstract][Full Text] [Related]
23. High-Dose Intravenous Immunoglobulin Therapy for Donor Specific Antibodies in Kidney Transplant Recipients with Acute and Chronic Graft Dysfunction: Updates on Previously Reported Cohorts.
Alfonso J; Gralla J; Klem P; Chan L; Wiseman AC; Cooper JE
Clin Transpl; 2014; ():161-70. PubMed ID: 26281141
[TBL] [Abstract][Full Text] [Related]
24. Significant association between chronic antibody-mediated rejection and donor-specific antibodies against HLA-DRB rather than DQB in renal transplantation.
Kobayashi T; Maruya E; Niwa M; Saji H; Kohara S; Katayama A; Takeda A; Watarai Y; Uchida K
Hum Immunol; 2011 Jan; 72(1):11-7. PubMed ID: 20974206
[TBL] [Abstract][Full Text] [Related]
25. A report of the epidemiology of de novo donor-specific anti-HLA antibodies (DSA) in "low-risk" renal transplant recipients.
Rebellato LM; Everly MJ; Haisch CE; Ozawa M; Briley KP; Parker K; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC
Clin Transpl; 2011; ():337-40. PubMed ID: 22755428
[TBL] [Abstract][Full Text] [Related]
26. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
[TBL] [Abstract][Full Text] [Related]
27. Effect of pretransplant human leukocyte antigen antibodies detected by solid-phase assay on heart transplant outcomes.
Gandhi MJ; DeGoey SR; Bundy K; Kremers WK; Knauer R; Pereira N; Edwards B; Kushwaha S; Daly RC
Transplant Proc; 2011 Dec; 43(10):3840-6. PubMed ID: 22172857
[TBL] [Abstract][Full Text] [Related]
28. Donor-specific HLA antibodies after transplantation are associated with deterioration in cardiac function.
Leech SH; Mather PJ; Eisen HJ; Pina IL; Margulies KB; Bove AA; Jeevanandam V
Clin Transplant; 1996 Dec; 10(6 Pt 2):639-45. PubMed ID: 8996758
[TBL] [Abstract][Full Text] [Related]
29. Donor-specific HLA antibodies in paediatric cardiac transplant recipients are associated with poor graft survival.
Irving C; Carter V; Parry G; Hasan A; Kirk R
Pediatr Transplant; 2011 Mar; 15(2):193-7. PubMed ID: 21199210
[TBL] [Abstract][Full Text] [Related]
30. HLA and MICA: targets of antibody-mediated rejection in heart transplantation.
Zhang Q; Cecka JM; Gjertson DW; Ge P; Rose ML; Patel JK; Ardehali A; Kobashigawa JA; Fishbein MC; Reed EF
Transplantation; 2011 May; 91(10):1153-8. PubMed ID: 21544036
[TBL] [Abstract][Full Text] [Related]
31. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation.
Brown CM; Abraham KA; O'Kelly P; Conlon PJ; Walshe JJ
Transplant Proc; 2009 Nov; 41(9):3690-2. PubMed ID: 19917368
[TBL] [Abstract][Full Text] [Related]
32. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
[TBL] [Abstract][Full Text] [Related]
33. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
[TBL] [Abstract][Full Text] [Related]
34. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival.
Ho EK; Vlad G; Vasilescu ER; de la Torre L; Colovai AI; Burke E; Deng M; Schwartz J; Marboe C; Mancini D; Opelz G; Suciu-Foca N
Hum Immunol; 2011 Jan; 72(1):5-10. PubMed ID: 20971146
[TBL] [Abstract][Full Text] [Related]
35. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment.
Stegall MD; Gloor JM
Curr Opin Organ Transplant; 2010 Feb; 15(1):8-10. PubMed ID: 19890210
[TBL] [Abstract][Full Text] [Related]
36. The role of therapeutic apheresis in the treatment of acute antibody-mediated kidney rejection.
Ahmed T; Senzel L
J Clin Apher; 2012; 27(4):173-7. PubMed ID: 22411078
[TBL] [Abstract][Full Text] [Related]
37. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis.
Tanriover B; Wright SE; Foster SV; Roush KS; Castillo-Lugo JA; Fa K; Levy FL; Mejia A
Transplant Proc; 2008 Dec; 40(10):3393-6. PubMed ID: 19100397
[TBL] [Abstract][Full Text] [Related]
38. Experience with antibody-mediated rejection in kidney allograft recipients.
Wade E; Goral S; Kearns J; Pierce E; Trofe J; Bloom R; Kamoun M
Clin Transpl; 2006; ():439-46. PubMed ID: 18365401
[TBL] [Abstract][Full Text] [Related]
39. Correlation of circulating donor-specific anti-HLA antibodies and presence of C4d in endomyocardial biopsy with heart allograft outcomes: a single-center, retrospective study.
Frank R; Molina MR; Wald JW; Goldberg LR; Kamoun M; Lal P
J Heart Lung Transplant; 2013 Apr; 32(4):410-7. PubMed ID: 23498162
[TBL] [Abstract][Full Text] [Related]
40. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
Stuckey LJ; Kamoun M; Chan KM
Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
